

One unit, three therapies*

V.A.C.Ulta[™] Negative Pressure Wound Therapy System

- V.A.C.® Negative Pressure Wound Therapy
- V.A.C. VeraFlo™ Instillation Therapy
- ABThera[™] Open Abdomen Negative Pressure Therapy

*when used with the appropriate dressings[†]



Choose V.A.C.® Therapy

PROVEN BENEFITS



Effective Healing

Mechanism of action promotes granulation tissue formation while providing a closed, moist wound healing environment.

Clinically Proven

V.A.C.® Therapy is the only negative pressure technology substantiated by more than 40 randomized, controlled, clinical trials and over 825 peer-reviewed articles.*

Cost-effective

In published studies on a variety of wound types, V.A.C.® Therapy has demonstrated the potential to help reduce:

- Length of stay¹⁻⁴
- Readmissions^{1,5}
- Need for surgeries^{1,6}

*As of September 2013

V.A.C.® **Therapy** promotes wound healing through well-established mechanisms of action.



Macrostrain:


- Decreases wound margins
- Removes exudate
- Reduces edema
- Removes infectious material



Microstrain:7-10

Promotes granulation tissue formation and perfusion by means of:

- Cell proliferation
- Fibroblast migration



Choose V.A.C. VeraFlo™ Therapy

ADDITIONAL THERAPEUTIC BENEFITS

V.A.C. VeraFlo™ Therapy is for wounds that would benefit from instillation therapy, such as:

- Contaminated wounds with instillation of topical wound cleansers.
- **Infected wounds** with instillation of appropriate topical wound solutions; these wounds also benefit from the removal of infectious materials in the V.A.C.® Therapy cycle.

Bench and preclinical studies:

- In a bench top study evaluating the potential for cross contamination: V.A.C. VeraFlo™ Therapy provided contained controlled wound irrigation without bacterial aerosolization. Standard manual cleansing techniques demonstrated significant bacterial aerosolization 6 inches from the simulated wound site (p<0.05).¹²
- In a porcine study with saline instillation: 7 days of V.A.C. VeraFlo™ Therapy using V.A.C. VeraFlo™ Dressings showed a 43% increase in wound fill compared to NPWT using V.A.C.® GranuFoam™ Dressings (p<0.05). V.A.C. VeraFlo™ Therapy cycles utilized a 5-minute soak time followed by 2.5 hours of V.A.C.® Therapy.¹¹

These results have not yet been confirmed in human studies.

V.A.C. VeraFlo™ Therapy provides:

Volumetric Delivery

With a pump for automated delivery of topical wound solutions.

Fill Assist

Helps determine the correct instill volume.

Dressing Soak

Instills topical wound solutions into the wound for easier dressing removal and increased patient comfort.

V.A.C. VeraFlo[™] Therapy combines the benefits of V.A.C.[®] Therapy with automated solution distribution and removal. V.A.C. VeraFlo[™] Therapy can help:



Cleanse

the wound with instillation of topical wound cleansers in a consistent, controlled manner




Treat

the wound with the instillation of appropriate topical antimicrobial and antiseptic solutions and the removal of infectious material



Ноз

the wound and prepare for primary or secondary closure



V.A.C.Ulta[™] Therapy Accessories

WITH ALL THE RIGHT PIECES

V.A.C. VeraT.R.A.C.™ Technology

Enhancement of SensaT.R.A.C.™ Technology for delivery of negative pressure wound therapy, as well as delivery and removal of topical wound solutions.

V.A.C. VeraT.R.A.C.™ Pad





V.A.C. VeraLink™ Cassette

Holds and delivers user-provided wound solutions.



Delivery and removal through a single pad.

D th

Delivery and removal through separate pads.

V.A.C. VeraFlo™ Dressings

Provide even distribution of wound solutions across the wound bed.

V.A.C. VeraFlo[™] Dressing



Promotes granulation tissue formation and is appropriate for wounds when using V.A.C. VeraFlo™ Therapy.





Allows clinicians flexibility in addressing wounds with complex geometries and is appropriate for wounds when using V.A.C. VeraFlo™ Therapy.

Dressing Property	V.A.C.® GranuFoam™ Dressing	V.A.C.® WhiteFoam Dressing	V.A.C. VeraFlo™ Dressing	V.A.C. VeraFlo Cleanse™ Dressing
				Gr
Material	Black Polyurethane ether	White Polyvinyl alcohol	Black Polyurethane ester	Grey Polyurethane ester
Open cell reticulated	Yes	No	Yes	Yes
Pore size	400-600 microns all directions	60-270 microns	400-600 microns	133-600 microns depends on direction
Relative hydrophobicity* (lowest value = highest level of hydrophobicity)	1	4	2	3
Shape	Variable shapes/sizes	Sheets	V.A.C. VeraFlo™ Sm & Med: Spiral cut sheet V.A.C. VeraFlo™ Lg: Block foam pre-cut	Rod with center perforations for ease of separation into halves
Tensile strength - Dry	Baseline	3 times greater than baseline	1.7 times greater than baseline	2.5 times greater than V.A.C. VeraFlo™ Dressing™ dry
Tensile strength - Wet	Baseline	3.7 times greater than baseline	1.5 times greater than baseline	3 times greater than V.A.C. VeraFlo™ Dressing™ wet
7 day granulation tissue formation** (Swine model data) ¹³	Therapy Applied			
	V.A.C. [®] Therapy	V.A.C.® Therapy	V.A.C. VeraFlo™ Therapy (Saline)	V.A.C. VeraFlo™ Therapy (Saline)
	Results			
	Baseline	20% less than baseline	43% greater than baseline	• 37% greater than V.A.C.® WhiteFoam Dressing with V.A.C.® Therapy
				• 24% less than V.A.C. VeraFlo™ Dressing with V.A.C. VeraFlo™ Therapy

^{*}Lowest value = highest level of hydrophobicity.



^{**}Granulation thickness based on histology; results have not yet been confirmed in human studies.



Enhanced Graphic User Interface

Intuitive touch screen menu with fewer screens to initiate therapy

Simple therapeutic programming

Customized Pressure Algorithms

Continuous negative pressure (from -25 to -200mmHg)

Dynamic Pressure Control is the evolution of intermittent therapy that maintains minimum negative pressure levels between cycles, helping to prevent leaks and fluid accumulation that can occur when there is no negative pressure at the wound site

Proven V.A.C.® Therapy System

Compatible for use with existing V.A.C.® Therapy System accessories:

SensaT.R.A.C.™ Technology provides continuous feedback for enhanced negative pressure accuracy.

V.A.C.® GranuFoam™ Dressings help promote granulation tissue formation and facilitate exudate removal.

V.A.C.® Canisters collect exudate.

Seal Check™ Leak Detector offers instant feedback to help identify leaks.

When using V.A.C.Ulta™ Therapy Unit for V.A.C.® Therapy only, it is compatible with V.A.C.® Dressings featuring SensaT.R.A.C.™ Technology.

V.A.C.ULTA™ SYSTEM ORDERING INFORMATION			
Part Number	Description		
ULTDEV01/US	V.A.C.Ulta™ Therapy Unit, United States		
ULTVFL05SM	V.A.C. VeraFlo™ Dressing, 5-pack, Small		
ULTVFL05MD	V.A.C. VeraFlo™ Dressing, 5-pack, Medium		
ULTVFL05LG	V.A.C. VeraFlo [™] Dressing, 5-pack, Large		
ULTVCL05MD	V.A.C. VeraFlo Cleanse™ Dressing, 5-pack, Medium		
ULTLNK0500	V.A.C. VeraLink™ Cassette, 5-pack		
400230	Prontosan® Wound Irrigation Solution with Adapter, case of 10		
ULTDUO0500	V.A.C. VeraT.R.A.C. Duo™ Tube Set, 5-pack		
M8275063/5	500 mL InfoV.A.C.® Canister with Gel		
M8275093/5	1,000 mL InfoV.A.C.® Large Canister with Gel		



†The dressings to be used with each therapy option are: 1) V.A.C.® Therapy using V.A.C.® GranuFoam™ and V.A.C.® WhiteFoam Dressings, 2) V.A.C. VeraFlo™ Instillation Therapy using V.A.C. VeraFlo™ and V.A.C. VeraFlo™ and V.A.C. VeraFlo™ SensaT.R.A.C.™ Open Abdomen Negative Pressure Therapy using ABThera™ SensaT.R.A.C.™ Open Abdomen Dressing. Do not use V.A.C. VeraFlo™ Therapy when using the ABThera™ SensaT.R.A.C.™ Open Abdomen Dressing. Visit www.openabdomen.com for more information on ABThera™ Open Abdomen Negative Pressure Therapy.

- 1. Baharestani MM, Gabriel A. Use of negative pressure wound therapy in the management of infected abdominal wounds containing mesh: an analysis of outcomes. Int Wound J, 2011; 8:118-125.
- 2. Blume PA, Walters J, Payne W, et al. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care. 2008; 31(4):631-636.
- Zannis J, Angobaldo J, Marks M, et al. Comparison of fasciotomy wound closures using traditional dressing changes and the vacuum-assisted closure device. Ann Plast Surg. 2009; 62: 407-409.
- 4. Schwien T, Gilbert J, Lang C. Pressure Ulcer prevalence and the role of negative pressure wound therapy in home health quality outcomes. OWM. 2005; 51 (9): 47-60.
- 5. Page JC, Newswander B, Schwenke DC, et al. Retrospective analysis of negative pressure wound therapy in open foot wounds with significant soft tissue defects. Adv. Skin Wound Care. 2004; 17(7):354-364. Retrospective study N=47, P=0.028.
- Apelqvist J, Armstrong DG, Lavery LA, et al. Resource utilization and economic costs of care based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabetic foot wounds. Am J Surg. 2008; 195(6): 782-788.
- 7. McNulty A, Spranger I, Courage J, et al. The consistent delivery of negative pressure to wounds using reticulated, open cell foam and regulated pressure feedback. Wounds. 2010 May;22(5):114-120.
- 8. Saxena V, Hwang C-W, Huang S, et al. Vacuum-assisted closure: microdeformations of wounds and cell proliferation. Plastic and Reconstructive Surgery. 2004 Oct;114(5):1086-1096; discussion 1097-8.
- 9. McNulty AK, Schmidt M, Feeley T, Kieswetter K. et al. Effects of negative pressure wound therapy on fibroblast viability, chemotactic signaling, and proliferation in a provisional wound (fibrin) matrix. Wound Repair Regen. 2007 November 1;15(6):838-46.
- 10. McNulty AK, Schmidt M, Feeley T, et al. Effects of negative pressure wound therapy on cellular energetics in fibroblasts grown in a provisional wound (fibrin) matrix. Wound Repair Regen. 2009 March 1;17(3):192-9.
- 11. Lessing C, Slack P, Hong KZ, et al. Negative pressure wound therapy with controlled saline instillation (NPWTi): dressing properties and granulation response in vivo. Wounds. 2011 October 1;23(10):309-19.
- 12. Allen D, Bondre IL, McNulty AK. Comparison of bacterial aerosolization during wound cleansing via two methods: Pulsed lavage and normal saline instillation in conjuction with negative pressure wound therapy. Wound Repair and Regeneration. 18[2], A41. 3-1-2010.
- 13. KCI data on file



For more information about the V.A.C.Ulta[™] Therapy System, contact us at **1-800-275-4524** or visit **www.vaculta.com**



NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for KCI products and therapies. Please consult a physician and product instructions for use prior to application. Rx only.



^{*}V.A.C.Ulta™ Therapy Unit is compatible with all the InfoV.A.C.® Canisters